2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Tumor-Agnostic
3
Breast
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
48
Everolimus
40
Magnetic Resonance Spectroscopy
21
lanreotide
17
Temozolomide
17
gallium Ga 68 dotatate
15
Octreotide
15
pembrolizumab
13
Nivolumab
13
surufatinib
12
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
Sunitinib
10
pasireotide
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
Lutetium-177
9
3-Iodobenzylguanidine
9
Ga(III)-DOTATOC
8
Carboplatin
8
telotristat ethyl
6
copper dotatate CU-64
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Ipilimumab
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Poly(ADP-ribose) Polymerase Inhibitors
×
NET
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled